- Home
- SHOT vs ANTX Comparison
SHOT vs ANTX Comparison
Compare SHOT & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- ANTX
- Stock Information
- Founded
- SHOT 2018
- ANTX 2017
- Country
- SHOT United States
- ANTX United States
- Employees
- SHOT N/A
- ANTX N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- SHOT Health Care
- ANTX Health Care
- Exchange
- SHOT Nasdaq
- ANTX Nasdaq
- Market Cap
- SHOT 30.4M
- ANTX 33.2M
- IPO Year
- SHOT 2020
- ANTX 2022
- Fundamental
- Price
- SHOT $0.47
- ANTX $1.10
- Analyst Decision
- SHOT
- ANTX Buy
- Analyst Count
- SHOT 0
- ANTX 2
- Target Price
- SHOT N/A
- ANTX $2.00
- AVG Volume (30 Days)
- SHOT 5.2M
- ANTX 258.4K
- Earning Date
- SHOT 08-13-2025
- ANTX 08-12-2025
- Dividend Yield
- SHOT N/A
- ANTX N/A
- EPS Growth
- SHOT N/A
- ANTX N/A
- EPS
- SHOT N/A
- ANTX N/A
- Revenue
- SHOT $573,336.00
- ANTX N/A
- Revenue This Year
- SHOT N/A
- ANTX N/A
- Revenue Next Year
- SHOT N/A
- ANTX N/A
- P/E Ratio
- SHOT N/A
- ANTX N/A
- Revenue Growth
- SHOT 69.32
- ANTX N/A
- 52 Week Low
- SHOT $0.23
- ANTX $0.87
- 52 Week High
- SHOT $1.77
- ANTX $3.07
- Technical
- Relative Strength Index (RSI)
- SHOT 59.24
- ANTX 48.42
- Support Level
- SHOT $0.39
- ANTX $1.05
- Resistance Level
- SHOT $0.56
- ANTX $1.10
- Average True Range (ATR)
- SHOT 0.08
- ANTX 0.04
- MACD
- SHOT 0.01
- ANTX 0.00
- Stochastic Oscillator
- SHOT 66.23
- ANTX 50.00
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.